To animate the Banner
Talent Recruitment
Apply for post
Recruitment Position
Place of work
Number of Recruits
Salary Treatment
ICP-248
ICP-248 is a new oral and highly selective BCL2 inhibitor. BCL2 is an important regulatory protein of apoptosis pathway, and its abnormal expression is related to the occurrence and development of a variety of malignant hematological tumors. ICP-248 selectively inhibit BCL2 and restore the mechanism of tumor cell death, so as to exert anti-tumor effect. The clinical trial of ICP-248 combined with orbitinib in the first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has completed the first patient administration in China. ICP-248 demonstrated good safety and efficacy in a phase I study. All patients achieved an objective response at the 100 mg once daily dose, with a complete response rate (CR) of 50%. The ICP-248 aims to treat a variety of malignant blood tumors with single drug or combination, and has a broad development space and significant potential in combination with Obutib.
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
Contact Information
Monday to Friday 9:00~17:00
Rooms 801-808 and 901-908, Building H, No. 3 Jiu Quan Road, Huangpu District, Guangzhou City
Copyright©2024 Virotech Pharmaceutical Technology Co., Ltd.